pSivida Corp. has signed a funded technology evaluation agreement with a leading global pharmaceutical company that will evaluate pSivida’s Durasert and Tethadur technologies for ophthalmology products. The Durasert technology is designed to deliver specific quantities of drugs directly to a target site at controlled rates for predetermined periods of time, and the Tethadur technology is for the delivery of proteins, peptides and antibodies.   “We are extremely pleased to be working with another...